BTOG 2020 | Chemoimmunotherapy, the UK & extensive-stage SCLC

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, discusses chemoimmunotherapy for extensive-stage small cell lung cancer (SCLC) commenting on whether UK clinical practice will change or persist with regards to this form of therapy. Dr Newsom-Davis specifically draws from the IMpower133 trial (NCT02763579), which investigated carboplatin plus etoposide with or without atezolizumab. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.